CD8⁺ T cell response in QuantiFERON-TB Gold Plus testing was associated with tuberculosis recurrence: a 2-year prospective study

References

• Vega V, Rodríguez S, Van der Stuyft P, et al. Recurrent TB: a systematic review and meta-analysis of the incidence rates and the proportions of relapses and reinfections. Thorax. 2021;76(5):494–502. doi: 10.1136/thoraxjnl-2020-215449.
   PubMed Web of Science ®Google Scholar
• Shen X, Yang C, Wu J, et al. Recurrent tuberculosis in an urban area in China: relapse or exogenous reinfection? Tuberculosis (Edinb). 2017;103:97–104. doi: 10.1016/j.tube.2017.01.007.
   PubMed Web of Science ®Google Scholar
• Lin Y, Lin H, Xiao L, et al. Tuberculosis recurrence over a 7-year follow-up period in successfully treated patients in a routine program setting in China: a prospective longitudinal study. Int J Infect Dis. 2021;110:403–409. doi: 10.1016/j.ijid.2021.07.057.
   PubMed Web of Science ®Google Scholar
• Zong Z, Huo F, Shi J, et al. Relapse versus reinfection of recurrent tuberculosis patients in a national tuberculosis specialized hospital in Beijing, China. Front Microbiol. 2018;9:1858. doi: 10.3389/fmicb.2018.01858.
   PubMed Web of Science ®Google Scholar
• Liu Q, Qiu B, Li G, et al. Tuberculosis reinfection and relapse in Eastern China: a prospective study using whole-genome sequencing. Clin Microbiol Infect. 2022;28(11):1458–1464. doi: 10.1016/j.cmi.2022.05.019.
   PubMed Web of Science ®Google Scholar
• Shao Y, Song H, Li G, et al. Relapse or re-infection, the situation of recurrent tuberculosis in Eastern China. Front Cell Infect Microbiol. 2021;11:638990. doi: 10.3389/fcimb.2021.638990.
   PubMed Web of Science ®Google Scholar
• Xin H, Zhang H, Yang S, et al. 5-Year follow-up of active tuberculosis development from latent infection in rural China. Clin Infect Dis. 2020;70(5):947–950. doi: 10.1093/cid/ciz581.
   PubMed Web of Science ®Google Scholar
• Houben RMGJ, Menzies NA, Sumner T, et al. Feasibility of achieving the 2025 WHO global tuberculosis targets in South Africa, China, and India: a combined analysis of 11 mathematical models. Lancet Glob Health. 2016;4(11):e806-15–e815. doi: 10.1016/S2214-109X(16)30199-1.
   Web of Science ®Google Scholar
• Global tuberculosis report 2023. Geneva: World Health Organization; 2023 [cited 2024 Jan 31]. Available from: https://www.who.int/publications/i/item/9789240083851
   Google Scholar
• Qiu B, Wu Z, Tao B, et al. Risk factors for types of recurrent tuberculosis (reactivation versus reinfection): a global systematic review and meta-analysis. Int J Infect Dis. 2022;116:14–20. doi: 10.1016/j.ijid.2021.12.344.
   PubMed Web of Science ®Google Scholar
• Xin H, Cao X, Zhang H, et al. Protective efficacy of 6-week regimen for latent tuberculosis infection treatment in rural China: 5-year follow-up of a randomised controlled trial. Eur Respir J. 2022;60(1):2102359. doi: 10.1183/13993003.02359-2021.
   PubMed Web of Science ®Google Scholar
• Lee MR, Chang CH, Chang LY, et al. CD8 response measured by QuantiFERON-TB gold plus and tuberculosis disease status. J Infect. 2019;78(4):299–304. doi: 10.1016/j.jinf.2019.01.007.
   PubMed Web of Science ®Google Scholar
• Barcellini L, Borroni E, Brown J, et al. First evaluation of QuantiFERON-TB gold plus performance in contact screening. Eur Respir J. 2016;48(5):1411–1419. doi: 10.1183/13993003.00510-2016.
   PubMed Web of Science ®Google Scholar
• Darmawan G, Liman LMS, Hamijoyo L, et al. Comparison of interferon-gamma production between TB1 and TB2 tubes of QuantiFERON-TB gold plus: a meta-analysis. Clin Chem Lab Med. 2023;61(12):2067–2075. doi: 10.1515/cclm-2023-0293.
   PubMed Web of Science ®Google Scholar
• Behr MA, Edelstein PH, Ramakrishnan L. Revisiting the timetable of tuberculosis. BMJ. 2018; 362:k2738. doi: 10.1136/bmj.k2738.
   PubMedGoogle Scholar
• National Health and Family Planning Commission of the People’s Republic of China. Classification of tuberculosis (WS196-2017). 2017 [cited 2018 Dec]. Available from: http://www.nhc.gov.cn/ewebeditor/uploadfile/2017/11/20171128164208411.pdf
   Google Scholar
• QIAGEN. QuantiFERON-TB Gold Plus ELISA Kit Package Insert. https://www.qiagen.com/us/resources/resourcedetail?id=ac068fc7-a994-4443-ac7c-dda43ce2bc5e&lang=en.
   Google Scholar
• National Health and Family Planning Commission of the People’s Republic of China. Diagnostic Criteria for Tuberculosis (WS 288-2017). 2017 [cited 2018 Dec]. Available from: http://www.nhc.gov.cn/ewebeditor/uploadfile/2017/11/20171128164254246.pdf
   Google Scholar
• Kobashi Y, Shimizu H, Mouri K, et al. Clinical evaluation of QuantiFERON TB-2G test in patients with healed pulmonary tuberculosis. J Infect Chemother. 2009;15(5):288–292. doi: 10.1007/s10156-009-0706-8.
   PubMed Web of Science ®Google Scholar
• Xin H, Zhang H, Liu J, et al. Mycobacterium Tuberculosis infection among the elderly in 20 486 rural residents aged 50-70 years in zhongmu county, China. Clin Microbiol Infect. 2019;25(9):1120–1126. doi: 10.1016/j.cmi.2019.01.021.
   PubMed Web of Science ®Google Scholar
• Bae W, Park KU, Song EY, et al. Comparison of the sensitivity of QuantiFERON-TB gold in-tube and T-SPOT.TB according to patient age. PLoS One. 2016;11(6):e0156917. doi: 10.1371/journal.pone.0156917.
   PubMed Web of Science ®Google Scholar
• Pan L, Jia H, Liu F, et al. Risk factors for false-negative T-SPOT.TB assay results in patients with pulmonary and extra-pulmonary TB. J Infect. 2015;70(4):367–380. doi: 10.1016/j.jinf.2014.12.018.
   PubMed Web of Science ®Google Scholar
• Viana Machado F, Morais C, Santos S, et al. Evaluation of CD8+ response in QuantiFERON-TB gold plus as a marker of recent infection. Respir Med. 2021;185:106508. doi: 10.1016/j.rmed.2021.106508.
   PubMed Web of Science ®Google Scholar
• Pérez-Recio S, Pallarès N, Grijota-Camino MD, ESCMID Study Group for Mycobacterial Infections (ESGMYC) and the Mycobacteria Study Group (GEIM) of the Spanish Society of Clinical Microbiology and Infectious Diseases (SEIMC)., et al. Identification of recent tuberculosis exposure using QuantiFERON-TB gold plus, a multicenter study. Microbiol Spectr. 2021; 9(3):e0097221. doi: 10.1128/Spectrum.00972-21.
   PubMed Web of Science ®Google Scholar
• Marx FM, Dunbar R, Enarson DA, et al. The temporal dynamics of relapse and reinfection tuberculosis after successful treatment: a retrospective cohort study. Clin Infect Dis. 2014;58(12):1676–1683. doi: 10.1093/cid/ciu186.
   PubMed Web of Science ®Google Scholar